Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections

 
• By Joseph Haas
  
IV solution in a child's patients hand
Cidara hopes its weekly I.V. antifungal will improve therapy for Candida infections
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D